Mandibular Advancement Devices Can Address Both OSA and Bruxism
A custom-made, titratable mandibular advancement device (MAD) is the single oral appliance that can effectively treat both obstructive sleep apnea and sleep-related bruxism simultaneously. 1
How MADs Work for Both Conditions
MADs stabilize the lower jaw in a forward and downward position, which:
- Maintains airway patency during sleep by advancing the mandible and increasing upper airway volume 1
- Significantly reduces sleep bruxism activity by 39-47% from baseline, with the reduction occurring regardless of the degree of mandibular protrusion 2
- Decreases jaw-closing muscle activity related to respiratory arousals, which are a key trigger for bruxism episodes in OSA patients 3
Evidence for Dual Treatment Effect
Recent research demonstrates that MAD therapy reduces both conditions through interconnected mechanisms:
- Both CPAP and MAD therapies significantly reduce sleep bruxism in OSA patients, with MAD showing a 60% reduction rate in bruxism episodes 4
- Total sleep bruxism episodes decrease significantly with MAD therapy (p < 0.001), alongside reductions in apnea-hypopnea index 5
- The mechanism appears multifactorial: MADs reduce respiratory events and respiratory-related arousals that trigger bruxism, while also providing direct mechanical stabilization 5, 6
Critical Device Specifications
For a MAD to effectively treat both conditions, it must meet these guideline-based criteria 1:
- Custom-made and titratable (not prefabricated)
- Engages both maxillary and mandibular arches
- Allows incremental advancement of ≤1mm with at least 5mm total adjustment range
- Maintains stable retention to teeth or implants
- Permits reversible adjustments during titration
- Reinforced design to withstand bruxism forces without breakage 2
Important Clinical Considerations
Contraindications that would prevent dual treatment:
- Severe periodontal disease
- Severe pre-existing temporomandibular disorders
- Inadequate dentition or retention
- Completely edentulous arches without implants 1
Common pitfall: Using non-titratable or prefabricated devices will compromise treatment efficacy for OSA and may not adequately address bruxism 7, 1.
Follow-Up Requirements
Objective sleep testing is mandatory to confirm treatment efficacy for OSA, even when bruxism symptoms improve 7, 1. The protocol should include:
- Initial polysomnography for OSA diagnosis
- Follow-up sleep testing with the MAD in place after final adjustments 1
- Evaluation every 6 months for the first year, then annually 1
- Coordination between sleep physician and qualified dentist for device adjustments and treatment monitoring 1
Nuances in Treatment Response
The relationship between OSA improvement and bruxism reduction is not always linear 5. Some patients show:
- Bruxism reduction even without complete OSA resolution
- Changes in arousal patterns during REM sleep that affect both conditions
- Individual variability requiring personalized titration 6
If MAD therapy proves sub-therapeutic for OSA, combination therapy with CPAP plus the oral appliance for bruxism protection may be considered 1.
Monitoring for Side Effects
Short-term effects (first few weeks) include hypersalivation, dry mouth, dental pain, and TMD discomfort—most are transient 1. Long-term monitoring should assess for occlusal changes including decreased overbite/overjet and tooth proclination 1.